Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing eye-care market.
Cytokinetics (NASDAQ:CYTK – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation. Analyst Ratings This is a breakdown of current recommendations […]
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass., May 22, 2024 Invivyd, Inc. , a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent.
Invivyd, Inc. announced that two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, were elected to its Board of Directors at the annual meeting of stockholders on May 21, 2024. Dr..